APONTIS PHARMA: START study published in scientific journal - Lower incidence of cardiovascular events with Single Pill therapy

DGAP-News: APONTIS PHARMA AG / Key word(s): Scientific publication
16.03.2022 / 07:30
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA: START study published in scientific journal - Lower incidence of cardiovascular events with Single Pill therapy

Monheim am Rhein, 16 March 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, announced that data from the healthcare research study called "START" on the reduction of cardiovascular events, which is unique in this scope, have been published in the peer-reviewed journal "Integrated Blood Pressure Control". The authors conclude from the findings that a single-pill therapy approach should generally be preferred for cardiovascular patients on long-term therapy to improve the prognosis of these patients.

In the START study (Effect of Single pill combinations on Treatment Adherence and persistence as well as on clinical and pharmacoeconomic outcomes in the Real-world Treatment of hypertension, coronary heart disease, hyperlipidemia and in secondary prevention of cardiovascular events: A claims data analysis), several cardiovascular event rates (including mortality, myocardial infarction and stroke) were compared between a therapy of seven single pills and a therapy with the respective loose combination of the corresponding single active ingredients.

In total, data from 59,336 patients were included in the evaluation, which led to the following results in favor of Single Pill therapy, among others:

• a significantly higher compliance (therapy adherence)
• lower all-cause mortality
• lower cardiovascular event rates
• a reduced number of total hospitalizations

"The START study has shown for the first time under real-world conditions in patients with health insurance in Germany that cardiovascular events and mortality can be better reduced by a Single Pill therapy concept than by a substance-matched multi-tablet strategy. This underlines the clinical importance of the Single Pill and supports the current recommendations of many medical societies," says study co-author Prof. Dr. Hans-Georg Predel.

"The now available, fully published results of the START study provide a reliable data basis to prove the clinical benefit of Single Pill therapy. As the Single Pill Company, it is our mission to ensure the therapeutic success of patients with highly effective medications and to highlight the therapeutic benefit of a Single Pill therapy concept, especially in view of the proven improvement in prognosis for patients. In this way, we provide the physicians in charge with a decision-making basis for substituting a substance-matched multi-tablet strategy with a single pill," said Thomas Milz, Chief Product Officer of APONTIS PHARMA AG.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Presse Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330

16.03.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de